样式 发表于 2025-3-25 06:49:30

High Throughput Screening for Novel Anti-Inflammatories

一再烦扰 发表于 2025-3-25 08:23:32

http://reply.papertrans.cn/43/4266/426537/426537_22.png

Debark 发表于 2025-3-25 13:32:57

Proteasome inhibitors,quent-ly studied is the 20S proteasome, a 700 kDa complex which catalyzes at least five proteolytic activities. The 20S proteasome is the catalytic core of the 26S proteasome, a larger particle (2000 kDa) which also contains two copies of a 19S regulatory complex. The 26S form of the proteasome cata

MEAN 发表于 2025-3-25 16:23:16

http://reply.papertrans.cn/43/4266/426537/426537_24.png

尊敬 发表于 2025-3-25 21:25:51

Elastase inhibitors,us proteinases which are capable of hydrolyzing and thus degrading a variety of structural matrix proteins, among them elastin. Elastin is an insoluble protein responsible for the elastic properties of mammalian connective tissue and organs. Elastin is an extremely hydrophobic protein which is not a

Projection 发表于 2025-3-26 01:37:28

http://reply.papertrans.cn/43/4266/426537/426537_26.png

DUST 发表于 2025-3-26 07:01:01

http://reply.papertrans.cn/43/4266/426537/426537_27.png

Debility 发表于 2025-3-26 11:09:32

Selectin antagonists,nvestigation [.-.]. This interest is not only to understand their physiological roles, but also due to the fact that the lectins, through their carbohydrate recognition domains (CRDs), recognize carbohydrate chains present on invading bacteria, viruses, and parasites. Manifestation and recognition o

MODE 发表于 2025-3-26 14:54:16

Cell adhesion integrins as pharmaceutical targets,ellular matrix, soluble proteins, and pathogens. Leukocyte adhesiveness is dynamically regulated in response to various cellular stimuli such as exposure to chemoattractants and cross-linking of B and T cell receptors. The capacity to modulate integrin adhesiveness prevents cells from non-specific a

高射炮 发表于 2025-3-26 18:47:04

http://reply.papertrans.cn/43/4266/426537/426537_30.png
页: 1 2 [3] 4 5
查看完整版本: Titlebook: High Throughput Screening for Novel Anti-Inflammatories; Michael Kahn Book 2000 Birkhäuser Verlag 2000 chemistry.diseases.drug.drug discov